← Latest news 
Mankind eyes BSV after a 3x valuation surge in women’s health pharma turnaround
Business
Published on 24 April 2026
The surprise buyer: a niche pharma turned mega-target
A low-profile pharma firm, Advent controlled-BSV, has drawn major investor attention after a turnaround that tripled its valuation in five years. Its focus on specialised women’s health products and a strong research pipeline have helped drive the momentum. Now, Mankind is set to acquire BSV in a $1.6 billion deal, putting the company’s next growth phase in the spotlight.
- BSV’s turnaround helped triple its valuation in five years
- Women’s health specialisation and research pipeline are core strengths
- Mankind’s planned $1.6 billion acquisition raises growth expectations
- The deal highlights how niche pharma can attract big capital
Read the full story at The Economic Times
This summarization was done by Beige for a story published on 
The Economic Times